Focus on Anticoagulation Care

Back to articles

VTE prophylaxis for high-risk ambulatory patients with cancer

KEY POINT

Use of apixaban (Eliquis—Bristol-Myers Squibb, Pfizer) as thromboprophylaxis in intermediate- to high-risk ambulatory patients receiving chemotherapy for various types of cancers reduced the risk of venous thromboembolisms (VTEs) but increased the risk of major bleeding episodes compared with placebo, and use of rivaroxaban (Xarelto—Janssen) in high-risk ambulatory patients with cancer reduced the risk of VTEs or death from a VTE during the intervention period without increasing the risk of major bleeding, according to results from two trials published in the New England Journal of Medicine.

SOURCES

Carrier M, et al. Apixaban to prevent venous thromboembolism in patients with cancer. N Engl J Med. 2019;380(8):711–9.

Khorana AA, et al. Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer. N Engl J Med. 2019;380(8):720–8.

Agnelli G, et al. Direct oral anticoagulants for thromboprophylaxis in ambulatory patients with cancer. N Engl J Med. 2019;380(8):781–3.